Joint pain is a widespread health concern associated with aging, musculoskeletal disorders, sports injuries, and degenerative conditions. Increasing incidence of osteoarthritis and other joint-related disorders is creating sustained demand for effective pain management and minimally invasive treatment approaches.

The Joint Pain Injection Market was valued at US$ 3,667.45 million in 2020 and is projected to reach US$ 6,996.88 million by 2028, expanding at a CAGR of 8.5% during 2021–2028. The increasing prevalence of musculoskeletal conditions, rising sports-related injuries, and growing adoption of injectable therapies are among the key factors supporting this growth.

Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00003536

Rising Prevalence of Musculoskeletal Disorders Drives Demand

Musculoskeletal disorders represent a significant global healthcare burden and include osteoarthritis, rheumatoid arthritis, tendinitis, fibromyalgia, and other conditions affecting bones, muscles, and joints. The increasing prevalence of these disorders, particularly among aging populations, is generating a larger patient pool requiring pain management and mobility-enhancing therapies.

Osteoarthritis remains one of the major contributors to joint pain and disability. In the US, more than 32.5 million adults are affected by osteoarthritis, creating considerable demand for therapeutic interventions. Joint injections can provide localized treatment and are commonly used when conservative approaches do not provide adequate relief. Increasing awareness regarding non-surgical treatment options is therefore contributing to the adoption of injectable therapies.

Sports injuries are another important growth factor. Athletes and physically active populations frequently experience knee, shoulder, ankle, and other joint injuries. The need for faster pain relief and rehabilitation is encouraging healthcare professionals to consider injectable treatments as part of comprehensive management strategies.

Corticosteroid Segment Maintains Strong Position

Based on drug, the Joint Pain Injection Market is segmented into hyaluronic acid, corticosteroid, and others. The corticosteroid segment accounted for the largest share in 2020, representing 48.2% of the overall market. Corticosteroid injections are widely utilized because of their ability to reduce inflammation and provide relatively rapid symptomatic relief.

Hyaluronic acid injections are also gaining attention, particularly for osteoarthritis-related knee pain. These injections are intended to supplement the viscoelastic properties of synovial fluid and may help improve joint function and reduce discomfort in selected patients. Advancements in injection formulations and increasing clinical research are expected to support continued innovation across both corticosteroid and hyaluronic acid therapies.

The development of newer injectable products, including platelet-rich plasma and other biologically derived approaches, is further broadening treatment options. However, differences in clinical evidence, reimbursement policies, treatment costs, and regulatory requirements can influence adoption across regions.

Knee Applications Represent a Key Growth Area

By joint type, the market is categorized into knee, foot and ankle, shoulder and elbow, hip, and other applications. The knee segment held a leading position in 2020 and is anticipated to register the fastest growth during the forecast period, with a projected CAGR of approximately 9%.

The prominence of knee applications is closely associated with the high prevalence of knee osteoarthritis and sports injuries. Knee pain can significantly affect mobility and quality of life, increasing demand for therapies that can delay or complement surgical intervention.

Healthcare providers are increasingly evaluating injectable therapies based on patient characteristics, disease severity, previous treatment response, and expected clinical outcomes. As diagnostic capabilities and personalized treatment approaches improve, the use of targeted injections for specific joint conditions is expected to expand.

Hospital Pharmacies and Regional Expansion

Based on distribution channel, the Joint Pain Injection Market is segmented into retail pharmacies, hospital pharmacies, and others. Hospital pharmacies held the largest share in 2020, accounting for 42.3%. The segment benefits from the growing number of procedures performed in hospitals, specialty clinics, and orthopedic care settings.

North America dominated the market in 2020 with a 70.2% share and is expected to continue its strong growth trajectory, registering a CAGR of 8.7% during the forecast period. The US is projected to expand at a CAGR of 8.9%. High healthcare expenditure, advanced orthopedic care infrastructure, strong awareness of treatment alternatives, and a substantial patient population contribute to the region's leading position.

Europe is also supported by an aging population and increasing incidence of joint disorders, while Asia-Pacific presents significant growth opportunities due to improving healthcare infrastructure, expanding access to specialized care, and rising awareness of advanced pain-management treatments.

Competitive Landscape and Key Players

The competitive environment is characterized by pharmaceutical, biotechnology, and orthopedic healthcare companies developing and commercializing injectable therapies. Companies are focusing on product innovation, clinical development, geographic expansion, and strategic collaborations to strengthen their positions.

Key players include:

• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Zimmer Biomet Holdings, Inc.
• Anika Therapeutics, Inc.
• Ferring B.V.
• Chugai Pharmaceutical Co., Ltd.
• Bioventus Inc.
• Fidia Pharma USA Inc.
• Flexion Therapeutics, Inc.
• SEIKAGAKU CORPORATION
• OrthogenRx, Inc.

Product development and differentiation are becoming increasingly important as healthcare providers seek therapies offering improved efficacy, safety, convenience, and duration of symptom relief. At the same time, high costs associated with certain joint repair and injection therapies may limit adoption, particularly in price-sensitive healthcare systems.

Future Outlook

The Joint Pain Injection Market is positioned for substantial expansion through 2028, supported by the rising burden of osteoarthritis and other musculoskeletal disorders, increasing sports injuries, and growing preference for minimally invasive pain-management approaches. Continued innovation in injectable formulations, growing adoption of non-surgical interventions, and expanding access to orthopedic care are expected to create new opportunities for manufacturers and healthcare providers.

Related Report:

1) Benzodiazepine Drugs Market Size, Share & Demand by 2034

2) Critical Limb Ischemia Treatment Market Size, Trends & Growth by 2034

3) Periodontal Therapeutics Market Growth, Size, Share, Trends, Key Players and Forecast by 2034

About Us -

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish